Drugs / Brenetafusp
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04262466 | Feb 2020 → Oct 2026 expected | cancer | Immunocore Ltd | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07686367 | Sep 2026 → Nov 2027 expected | myxoid liposarcoma, synovial sarcoma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06112314 | Jun 2024 → Oct 2027 expected | melanoma | Immunocore Ltd | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | brenetafusp | “This phase II trial studies how well brenetafusp (IMC-F106C) works in treating patients with preferentially expressed antigen of melanoma (PRAME) positive synovial sarcoma and...” NCT07686367 ↗ |
| Known as | IMC-F106C | “Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated...” NCT04262466 ↗ |
| Modality | Protein / enzyme biologic | “Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®)” NCT04262466 ↗ |
| Route | Intravenous | “Brenetafusp IV infusions” NCT04262466 ↗ |